Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNN3 | Q9UGI6 | 11/20 | 0.37 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.36 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26870956 | 0.83 | PDE10A (0.53) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL12953881 | 0.83 | PDE10A (0.61) | PDE10AKDM4EKCNN3KCNN1KCNN2 | |
| SCHEMBL26870905 | 0.82 | PDE10A (0.51) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL21754101 | 0.81 | PDE10A (0.41) | PDE10AKDM4EKCNN3DGAT1MEN1 | |
| SCHEMBL21849086 | 0.81 | KDM4E (0.42) | PDE10AKDM4EKCNN3KCNN1KCNN2 | |
| SCHEMBL26871132 | 0.79 | PDE10A (0.49) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL26871232 | 0.79 | PDE10A (0.49) | PDE10AKCNN3KCNN1KCNN2MAPT | |
| SCHEMBL24965992 | 0.77 | PDE10A (0.38) | PDE10AKDM4EKCNN3KCNN1KCNN2 | |
| SCHEMBL27116430 | 0.77 | PDE10A (0.38) | PDE10AKDM4EKCNN3DGAT1 | |
| SCHEMBL27114778 | 0.77 | CCNT1 (0.38) | PDE10AKDM4EKCNN3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931677-B1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1934224-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | PDE10A 1590/4885KDM4E 731/4885KCNN3 3841/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | PDE10A 1177/4885KDM4E 462/4885KCNN3 4291/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | PDE10A 1590/4885KDM4E 731/4885KCNN3 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.